Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Non-compartmental analysis of interferon-α: Mean ± S.D. (CV%)

From: Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model

Group Dose Formulation Cmax(pg/mL) Median Tmax(h) AUClast(ng·h/mL)
Controla (N=8) 3 MIU Roferon-A® 43.27 ± 9.804 (22.66%) 6 0.9664 ± 0.9322 (96.46%)
1 (N=6) 9 MIU SR-IFN-α 28.33 ± 9.656 (34.08%) 18 2.072 ± 1.134 (54.73%)
2 (N=6) 18 MIU SR-IFN-α 62.12 ± 15.93 (25.64%) 24 5.373 ± 1.382 (25.72%)
3 (N=6) 27 MIU SR-IFN-α 65.73 ± 6.702 (10.20%) 24 5.544 ± 0.5509 (9.94%)
4 (N=6) 36 MIU SR-IFN-α 80.31 ± 9.859 (12.28%) 24 7.151 ± 1.132 (15.83%)
  1. aThere was not a separate control group, but data from a total of eight subjects (two subjects in each of the four groups) who received 3 MIU of Roferon-A® were shown.